» Articles » PMID: 34750023

Diagnosis of Soft Tissue Tumors Using Immunohistochemistry As a Surrogate for Recurrent Fusion Oncoproteins

Overview
Date 2021 Nov 9
PMID 34750023
Authors
Affiliations
Soon will be listed here.
Abstract

Soft tissue neoplasms encompass a broad spectrum of clinicopathologic manifestations. In a subset of soft tissue tumors, spanning a wide range of clinical behavior from indolent to highly aggressive, recurrent genetic translocations yield oncogenic fusion proteins that drive neoplastic growth. Beyond functioning as primary mechanisms of tumorigenesis, recurrent translocations represent key diagnostic features insofar as the presence of a particular oncogenic gene fusion generally points to specific tumor entities. In addition to more direct methods for identifying recurrent translocations, such as conventional cytogenetics or fluorescence in situ hybridization, immunohistochemistry for a component of the fusion oncoprotein increasingly is being used as a surrogate marker, exploiting the tendency of these fusion components to be distinctively overexpressed by translocation-bearing tumor cells. Diagnostic immunohistochemistry can also be used to identify the characteristic gene expression changes that occur downstream of oncogenic fusions. Here, we review the use of immunohistochemistry to detect surrogate markers of recurrent translocations in soft tissue tumors, focusing on the practical applications and limitations of this diagnostic approach.

Citing Articles

Nuclear DUX4 immunohistochemistry is a highly sensitive and specific marker for the presence of CIC::DUX4 fusion in CIC-rearranged sarcomas: a study of 48 molecularly confirmed cases.

Macedo R, Baranovska-Andrigo V, Pancsa T, Klubickova N, Rubin B, Kilpatrick S Histopathology. 2024; 86(3):423-432.

PMID: 39381843 PMC: 11707495. DOI: 10.1111/his.15341.

References
1.
Dagrada G, Spagnuolo R, Mauro V, Tamborini E, Cesana L, Gronchi A . Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol. 2015; 28(8):1074-83. DOI: 10.1038/modpathol.2015.70. View

2.
Charville G, Varma S, Forgo E, Dumont S, Zambrano E, Trent J . PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms. Am J Surg Pathol. 2016; 40(10):1305-15. DOI: 10.1097/PAS.0000000000000717. View

3.
Puls F, Agaimy A, Flucke U, Mentzel T, Sumathi V, Ploegmakers M . Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma. Am J Surg Pathol. 2020; 44(5):594-606. DOI: 10.1097/PAS.0000000000001423. View

4.
Doyle L, Tao D, Marino-Enriquez A . STAT6 is amplified in a subset of dedifferentiated liposarcoma. Mod Pathol. 2014; 27(9):1231-7. DOI: 10.1038/modpathol.2013.247. View

5.
Hung Y, Fletcher C, Hornick J . Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. Mod Pathol. 2016; 29(11):1324-1334. DOI: 10.1038/modpathol.2016.140. View